100 related articles for article (PubMed ID: 21322018)
1. The effect of drug treatment on neurogenesis in Parkinson's disease.
O'Sullivan SS; Johnson M; Williams DR; Revesz T; Holton JL; Lees AJ; Perry EK
Mov Disord; 2011 Jan; 26(1):45-50. PubMed ID: 21322018
[TBL] [Abstract][Full Text] [Related]
2. The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain.
van den Berge SA; van Strien ME; Korecka JA; Dijkstra AA; Sluijs JA; Kooijman L; Eggers R; De Filippis L; Vescovi AL; Verhaagen J; van de Berg WD; Hol EM
Brain; 2011 Nov; 134(Pt 11):3249-63. PubMed ID: 22075520
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
Palmer SJ; Eigenraam L; Hoque T; McCaig RG; Troiano A; McKeown MJ
Neuroscience; 2009 Jan; 158(2):693-704. PubMed ID: 18722512
[TBL] [Abstract][Full Text] [Related]
4. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease.
Degirmenci B; Yaman M; Haktanir A; Albayrak R; Acar M; Caliskan G
Neurosci Lett; 2007 Apr; 416(3):294-8. PubMed ID: 17317000
[TBL] [Abstract][Full Text] [Related]
5. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
7. The effects of levodopa on word intelligibility in Parkinson's disease.
De Letter M; Santens P; Van Borsel J
J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
[TBL] [Abstract][Full Text] [Related]
8. NPY promotes chemokinesis and neurogenesis in the rat subventricular zone.
Thiriet N; Agasse F; Nicoleau C; Guégan C; Vallette F; Cadet JL; Jaber M; Malva JO; Coronas V
J Neurochem; 2011 Mar; 116(6):1018-27. PubMed ID: 21175616
[TBL] [Abstract][Full Text] [Related]
9. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
10. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
11. [Drug therapy in Parkinson's disease].
van Hilten JJ; Roos RA
Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
[TBL] [Abstract][Full Text] [Related]
12. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.
Uchiyama T; Sakakibara R; Hattori T; Yamanishi T
Mov Disord; 2003 May; 18(5):573-8. PubMed ID: 12722172
[TBL] [Abstract][Full Text] [Related]
13. Psychophysiological approach in Parkinson's disease: L-dopa effects on preprogramming and control activity.
Fattapposta F; Pierelli F; My F; Mostarda M; Del Monte S; Parisi L; Serrao M; Locuratolo N; Amabile G
Neurol Sci; 2002 Sep; 23 Suppl 2():S73-4. PubMed ID: 12548350
[TBL] [Abstract][Full Text] [Related]
14. Disturbed intracortical excitability in early Parkinson's disease is l-DOPA dose related: a prospective 12-month paired TMS study.
Bares M; Kanovský P; Rektor I
Parkinsonism Relat Disord; 2007 Dec; 13(8):489-94. PubMed ID: 17449315
[TBL] [Abstract][Full Text] [Related]
15. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
[TBL] [Abstract][Full Text] [Related]
16. Does levodopa affect metaiodobenzylguanidine myocardial accumulation in Parkinson's disease?
Kishi M; Sakakibara R; Terada H; Ogawa E; Tateno T
Mov Disord; 2011 Feb; 26(3):563-4. PubMed ID: 21287597
[No Abstract] [Full Text] [Related]
17. Brain dopaminergic modulation associated with executive function in Parkinson's disease.
Farid K; Sibon I; Guehl D; Cuny E; Burbaud P; Allard M
Mov Disord; 2009 Oct; 24(13):1962-9. PubMed ID: 19672989
[TBL] [Abstract][Full Text] [Related]
18. L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Isobe C; Abe T; Terayama Y
J Clin Neurosci; 2010 Jun; 17(6):717-21. PubMed ID: 20356746
[TBL] [Abstract][Full Text] [Related]
19. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
Broussolle E
Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
[No Abstract] [Full Text] [Related]
20. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Yokochi M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
